Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease

Jiaxiang Zhang,[1,2] Timothy Rittman,[3] Cristina Nombela,[3] Alessandro Fois,[3] Ian Coyle-Gilchrist,[3] Roger A. Barker,[3] Laura E. Hughes[2,3] and James B. Rowe[2,3,4]

Progressive supranuclear palsy and Parkinson's disease have distinct underlying neuropathology, but both diseases affect cognitive function in addition to causing a movement disorder. They impair response inhibition and may lead to impulsivity, which can occur even in the presence of profound akinesia and rigidity. The current study examined the mechanisms of cognitive impairments underlying disinhibition, using horizontal saccadic latencies that obviate the impact of limb slowness on executing response decisions. Nineteen patients with clinically diagnosed progressive supranuclear palsy (Richardson's syndrome), 24 patients with clinically diagnosed Parkinson's disease and 26 healthy control subjects completed a saccadic Go/No-Go task with a head-mounted infrared saccadometer. Participants were cued on each trial to make a pro-saccade to a horizontal target or withhold their responses. Both patient groups had impaired behavioural performance, with more commission errors than controls. Mean saccadic latencies were similar between all three groups. We analysed behavioural responses as a binary decision between Go and No-Go choices. By using Bayesian parameter estimation, we fitted a hierarchical drift–diffusion model to individual participants' single trial data. The model decomposes saccadic latencies into parameters for the decision process: decision boundary, drift rate of accumulation, decision bias, and non-decision time. In a leave-one-out three-way classification analysis, the model parameters provided better discrimination between patients and controls than raw behavioural measures. Furthermore, the model revealed disease-specific deficits in the Go/No-Go decision process. Both patient groups had slower drift rate of accumulation, and shorter non-decision time than controls. But patients with progressive supranuclear palsy were strongly biased towards a pro-saccade decision boundary compared to Parkinson's patients and controls. This indicates a prepotency of responding in combination with a reduction in further accumulation of evidence, which provides a parsimonious explanation for the apparently paradoxical combination of disinhibition and severe akinesia. The combination of the well-tolerated oculomotor paradigm and the sensitivity of the model-based analysis provides a valuable approach for interrogating decision-making processes in neurodegenerative disorders. The mechanistic differences underlying participants' poor performance were not observable from classical analysis of behavioural data, but were clearly revealed by modelling. These differences provide a rational basis on which to develop and assess new therapeutic strategies for cognition and behaviour in these disorders.

1 School of Psychology, Cardiff University, Cardiff CF10 3AT, UK
2 Cognition and Brain Sciences Unit, Medical Research Council, Cambridge CB2 7EF, UK
3 Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 2QQ, UK
4 Behavioural and Clinical Neuroscience Institute, Cambridge, CB2 3EB, UK

Correspondence to: Jiaxiang Zhang,
School of Psychology,
Cardiff University,
Cardiff CF10 3AT, UK
E-mail: zhangj73@cardiff.ac.uk

Introduction

Parkinson's disease and progressive supranuclear palsy (PSP) are associated with many non-motor symptoms as well as the motor hallmarks of bradykinesia and rigidity. Despite very different underlying neuropathology (Hauw *et al.*, 1994; Litvan *et al.*, 1996b; Braak *et al.*, 2003), both disorders may lead to executive dysfunction and impulsivity. Impulse control disorders are severe in ~10% of patients with Parkinson's disease (Weintraub *et al.*, 2010), but patients are impaired in response inhibition and decision-making even in the absence of impulse control disorders, and also before they are exposed to any dopaminergic therapies (Obeso *et al.*, 2011; Nombela *et al.*, 2014; Ye *et al.*, 2014a). The Richardson's syndrome or 'classical' phenotype of PSP also causes impulsivity despite severe akinesia and apathy (O'Sullivan *et al.*, 2010; Burrell *et al.*, 2014). It manifests as delay intolerance, choice impulsivity, and behavioural decisions that increase the risk of falls, and it can exacerbate dysphagia and carer burden (Wedderburn *et al.*, 2008; Burrell *et al.*, 2014).

There are several candidate mechanisms by which PSP and Parkinson's disease may lead to impulsivity and poor response inhibition. For example, loss of subthalamic inhibition would lead to a bias towards action and away from response inhibition, by disinhibition of thalamocortical projections (Frank *et al.*, 2007; Averbeck *et al.*, 2014). Cortical neuropathology, especially in prefrontal and premotor circuits (Braak *et al.*, 2003; Brenneis *et al.*, 2004; Rae *et al.*, 2012) may also impair the appropriate accumulation of evidence for action and inhibition in a given context (Verbruggen and Logan, 2009), and impair the selection and execution of actions (Zhang *et al.*, 2012). Finally, changes in dopaminergic, serotonergic and noradrenergic innervation of the cortex and striatum can influence decision-making and response inhibition (Ye *et al.*, 2014a, b), while dopaminergic therapies themselves can increase risk-taking behaviours and impulsivity (Weintraub *et al.*, 2010).

The different features of PSP and Parkinson's disease mean that behavioural deficits in response inhibition may have different origins in these two disorders. In Parkinson's disease for example, the impulsive choice arising from dopaminergic stimulation is distinct from the impulsive choice arising from therapeutic deep brain stimulation of the subthalamic nucleus (Frank *et al.*, 2007).

We tested this hypothesis in two clinically diagnosed patient groups and a healthy control group on a saccadic Go/No-Go task (Fig. 1A). The reason for the use of saccadic measures is 2-fold: (i) the precision of the oculomotor system that enables accurate recording and modelling; and (ii) the advantage of measuring the time to initiate movement, not execution time, in patients with bradykinesia.

The underlying cognitive deficits were revealed by formalizing the Go/No-Go task as an accumulation-to-threshold decision process, which can be described by a drift-diffusion model (DDM) (Gomez *et al.*, 2007; Ratcliff and McKoon, 2008). This model provides a parsimonious account of complex behavioural phenomena, including response latency distributions (Ratcliff and Smith, 2004), speed accuracy trade-offs (Zhang and Rowe, 2014), and the effects of uncertainty on decision-making (Mulder *et al.*, 2012). The DDM also has direct neurophysiological evidence in support of it, for neurons in the superior colliculus (Ratcliff *et al.*, 2003) and cortex (Kim and Shadlen, 1999; Shadlen and Newsome, 2001), while related methods have been used to examine anatomical correlates from functional brain imaging data (Rowe *et al.*, 2010; Zhang *et al.*, 2012). This model-based approach has proven valuable and has already revealed the critical role of the subthalamic nuclei for motor inhibition under conditions of ambiguity or risk (Cavanagh *et al.*, 2011) and the effect of subthalamotomy on inhibitory behaviour (Obeso *et al.*, 2014).

Accurate fitting of the model in studies of animals and healthy participants often requires thousands of trials (Brunton *et al.*, 2013). This would not be tolerated by patients with neurodegenerative disorders. We therefore used a Bayesian parameter estimation approach to fit a hierarchical DDM that encompasses patient heterogeneity in terms of random sampling of individuals from a group-wise distribution (Wiecki *et al.*, 2013). By optimizing the model to fit both the distribution of response latencies and the accuracy of responses, the hierarchical DDM is efficient at reproducing behavioural data and the properties of generative decision processes, within a few trials.

The DDM assumes that a single accumulator integrates the momentary evidence over time. This accumulation process terminates when the accumulated evidence reaches an upper or a lower boundary, corresponding to the Go or No-Go decisions (Fig. 1B). Impulsive behaviour in the Go/No-Go task can be decomposed into different changes in parameters of the DDM, for example a baseline bias towards 'Go' decisions (Mulder *et al.*, 2012), or reduced accumulation rate for 'No-Go' decisions (Obeso *et al.*, 2014).

We predicted that both PSP and Parkinson's disease impair response inhibition but the hierarchical DDM would reveal different causes of these deficits in the two diseases. Knowledge of these mechanisms may not only increase our ability to detect such deficits, but would also enable the development of better mechanistic therapies.

Figure 1 Saccadic Go/No-Go task and the drift-diffusion model. (A) Participants fixated on green and red points overlapping at the centre of the screen. One of the two points disappeared and a saccadic target was presented on the left or right of the screen at an angle of $10°$ from the fixation point. Participants were instructed to make a saccade to the target if the remaining fixation point was green, or withhold their response if the remaining fixation point was red. **(B)** Examples of trajectories of the drift-diffusion model. Two decision boundaries (0 and a) represent the Go and No-Go decisions. The drift rate v represents the rate of accumulation. The diffusion process starts at a starting point between the two boundaries ($a*z$) until the accumulated evidence reaches one of the two boundaries. The predicted saccadic latency is the sum of the duration of the diffusion process and the non-decision time T_{er}.

Materials and methods

Participants

Sixty-nine participants were recruited. Demographic and clinical features of the participants are summarized in Table 1. Nineteen patients with PSP were recruited from a regional specialist clinic for PSP and related disorders at the Cambridge University Hospitals NHS Foundation Trust. Consensus clinical diagnostic criteria (Litvan et al., 1996a) for probable PSP were used by an experienced neurologist, identifying the Richardson's syndrome phenotype. To date, 10 of the clinically diagnosed patients have died and been recruited to the Cambridge Brain Bank as part of a separate research programme: all 10 had neuropathological confirmation of the diagnosis.

Twenty-four patients with idiopathic Parkinson's disease (Hoehn and Yahr stage I–III) were recruited through the Cambridge University Parkinson's Disease Research Clinic. All Parkinson's patients met the United Kingdom Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (Gibb and Lees, 1988). Patients with Parkinson's disease did

Table 1 Demographics and neuropsychological measures of participants with PSP, Parkinson's disease and healthy control subjects

	PSP (n = 19)	PD (n = 24)	Control (n = 26)
Age	68.37 ± 6.54	66.17 ± 10.15	66.58 ± 7.10
Gender	8 M / 11 F	13 M / 11 F	10 M / 16 F
MMSE	26.58 ± 3.73	28.29 ± 1.92	29.46 ± 0.95
ACE-R	79.89 ± 12.23	89.63 ± 8.72	94.62 ± 4.05
PSPRS	38.16 ± 16.89	–	–
UPDRS-III	–	33.88 ± 15.89	–

Values are mean ± standard deviation. PD = Parkinson's disease.

not have pathological confirmation. Additional inclusion criteria were: (i) non-demented at last clinical assessment (Mini-Mental State Examination score, MMSE ⩾ 24/30); (ii) no ongoing clinically significant depression (Beck Depression Inventory score ⩽ 18; Beck et al., 1988).

Twenty-six healthy control participants with no history of significant neurological or psychiatric disorders were recruited from the volunteer panel of the Medical Research Council Cognition and Brain Sciences Unit.

Participants underwent cognitive assessment using the Revised Addenbrooke's Cognitive Examination (ACE-R) and Mini-Mental State Examination. Disease severity was assessed by the PSP Rating Scale (PSPRS) (Golbe and Ohman-Strickland, 2007) and the Unified Parkinson Disease Rating Scale (UPDRS, part III motor subscale) (Fahn, 1986). All testing was performed with participant's taking their usual medication. The study was approved by the local research ethics committee. Written informed consent was obtained from all participants.

Task and procedure

All participants performed a saccadic Go/No-Go task (Fig. 1A; Nombela et al., 2014). Each participant sat at a distance of 1.5 m from a blank screen wearing a head-mounted saccadometer (Ober consulting) with a binocular infra-red scleral oculometer for measurement of horizontal movements. The infrared reflectance signals were recorded at 1 kHz and low pass filtered at 250 Hz, with 12 bit resolution. Three low-power lasers were mounted on the forehead plate and angled at $-10°$, $0°$ and $+10°$ azimuth for stimulus presentation. Because the device and target display moves with the head, a head restraint or a bite bar is not required.

Each experiment session consisted of 300 trials. At the beginning of each trial, the participants fixated on two central spots at $0°$ (one green, one red). After a random period between 1500 ms and 2500 ms, one of the central spots was extinguished and simultaneously a red target spot was presented with a $-10°$ or $+10°$ horizontal displacement. In 50% of the trials, the green central spot remained and the participants were required to make a saccade to the lateral target (Go trials). In the other 50% of trials, the red central spot remained and the participants were required to hold their saccade and maintain fixation (No-Go trials). The lateral target disappeared 250 ms after a saccade was made, or after a maximum duration of 1500 ms was reached. The order of the

target locations (leftwards and rightwards) and the trial type (Go and No-Go) were randomized within and across participants. A short series of 40 presentations of the targets were used at the beginning of the session for calibration.

Data preprocessing

Eye movement data were downloaded from the saccadometer to a laptop and preprocessed using an automated validation program in Latency Meter 2.3 (Ober consulting). The validation program removed erroneous trials due to blinks, as well as grossly abnormal profiles as determined by the instantaneous velocity, acceleration, and position of eye movement traces, and rejection criteria for either the peak velocity or saccadic duration (Ober *et al.*, 2003).

For trials with valid saccades, the saccadic latency was defined as the time interval between the target onset and the onset of the saccade. The saccadic latency data were pooled for leftward and rightward targets to increase statistical power, because the saccadic latencies did not significantly differ between the two target locations [$t(68) = 0.63$, $P = 0.53$, paired t-test]. Four behavioural measures were obtained for each participant: (i) the rate of omission errors in Go trials; (ii) the rate of commission errors in No-Go trials; (iii) mean saccadic latency in successful Go trials; and (iv) mean saccadic latency in No-Go trials with commission errors.

Hierarchical drift-diffusion model for the Go/No-Go task

The saccadic Go/No-Go task can be conceptualized as a rapid two-alternative forced choice between a Go decision and a No-Go decision (Gomez *et al.*, 2007). The decision process has been described by a widely accepted DDM (Ratcliff and McKoon, 2008). The model can be described by four parameters (Fig. 1B): boundary separation a indicating the distance between the two decision boundaries, drift rate v indicating the rate of evidence accumulation, *a priori* decision bias z indicating the starting point of the accumulator at stimulus onset, and non-decision time T_{er} indicating the time used for non-decision processes (e.g. stimulus encoding or response execution latencies).

Most decision-making tasks require selecting between two overt responses. For example, in a lexical decision task, participants are instructed to make 'word' or 'non-word' decisions by pressing one of two response buttons (Ratcliff *et al.*, 2004). In this case, the two decision boundaries in the DDM correspond to the two choice alternatives, and the model predicts the decision time for each choice as the latency of accumulator activity reaching the corresponding boundary. However, the Go/No-Go task differs from the classical binary decision tasks in that response time for a No-Go decision cannot be explicitly measured. In line with previous studies (Gomez *et al.*, 2007), we assumed an implicit lower decision boundary for No-Go decisions and an upper boundary for Go decisions (Fig. 1B), and fitted the DDM to individual participant's responses (i.e. the proportion of Go and No-Go choices) as well as the distributions of saccadic latencies (i.e. in Go trials with successful responses or in No-Go trials with commission errors).

The hierarchical DDM toolbox was used to fit the data (Wiecki *et al.*, 2013). The hierarchical model assumes that participants are random samples drawn from group-level distributions, and uses Bayesian statistical methods to simultaneously estimate parameter distributions at both the group level and the individual-participant level (Vandekerckhove *et al.*, 2011). The Bayesian approach has been shown to be more robust in recording model parameters than other methods such as maximum likelihood estimation when limited data are available (Jahfari *et al.*, 2013). This important feature greatly benefits the current study, because of substantial constraints on the duration of the task for patients.

We examined four variants of the DDM with different parameter constraints. The first model assumed an unbiased starting point ($z = 0.5$) and the same absolute value for the drift rate in the Go and No-Go conditions (i.e. if the drift rate in the Go condition is v, then the drift rate in the No-Go condition is $-v$). The second model assumed an unbiased starting point but allowed the drift rate to vary between the two conditions. The third model assumed variable starting points across participants and the same absolute value for the drift rate in the two conditions. The fourth model assumed variable starting points and different drift rates in the two conditions. Each model parameter had three group-level distributions corresponding to the three participant groups (PSP, Parkinson's disease and controls) and individual-level distributions for each participant.

For each model, we generated 15 000 samples from the joint posterior distribution of all model parameters by using Markov chain Monte Carlo methods (Gamerman and Lopes, 2006). The initial 5000 samples were discarded as burn-in to minimize the effect of initial values on the posterior inference (see Wiecki *et al.*, 2013 for more details of the procedure). Geweke statistic was used to assess the convergence of the Markov chains (Gelman *et al.*, 2004). Parameter estimates in all models were converged after 15 000 samples.

Statistical analysis

ANOVAs and *post hoc* t-tests were used for statistical analysis of the behavioural measures between groups. Statistical inference on model parameters was made by two complementary approaches. First, for each parameter at the individual-participant level, the mean of its posterior distribution was used as a point estimate for comparing between groups. Second, for each parameter at the group level, Bayesian inference was used to directly compare its posterior distribution between groups (Lindley, 1965; Berger and Bayarri, 2004; Gelman *et al.*, 2004; Kruschke, 2010). We use P to refer to classical frequentist P-values, and $P_{p|D}$ to refer to the proportion of posteriors supporting the testing hypothesis at the group level from Bayesian inference.

Model-based classification of individual patients

To investigate how well the model parameters can distinguish between the three participant groups, we used a three-way linear logistic regression classifier implemented in Weka (http://www.cs.waikato.ac.nz/ml/weka). For each participant, the feature space for classification included mean estimates of

the five model parameters from the best fitted model (a, z, T_{er}, v_{go}, and $v_{no\text{-}go}$). A leave-one-out cross-validation procedure was performed to optimize the use of this limited dataset. In each cross-validation fold, one participant was first removed and the remaining participants' data were used as a training set to build the classifier. The participant left out was then classified into one of the three groups (PSP, Parkinson's disease and controls), independently from the training set. Classification performance was evaluated by the hit rate, precision, and the area under the receiver operating characteristic (ROC) curve (AUC) of each class, averaged across all cross-validations.

To assess whether the model parameters provide better discrimination than simple behavioural measures, we performed the same classification procedure with a second feature space, which contained four raw behavioural measures (omission rate, commission rate, mean saccadic latencies in the Go and No-Go conditions).

We used permutation tests to evaluate whether DDM parameters are better than raw behavioural measures in the classification of a participant's group. Three evaluation criteria were used: weighted average of hit rate across the three classes, weighted average of precision, and weighted average of AUC. The significance of each criterion was determined by comparing the observed evaluation criterion with its distribution under the null hypothesis, which was generated by 100 000 random permutations of leave-one-out classification results between the two feature sets. The permutation P-value was then obtained by calculating the probability of the permuted samples exceeding the observed value in the data.

Results

Behavioural results

Details of participant demographics, disease severity and neuropsychological scores are given in Table 1. The three groups were well matched for age [$F(2,68) = 0.42$, $P = 0.66$] and gender ($P = 0.51$, chi-square test). As expected, cognitive performance differed significantly between groups [MMSE: $F(2,68) = 8.41$, $P < 0.001$; ACE-R: $F(2,68) = 16.34$, $P < 0.00001$]. Both patient groups had lower MMSE scores than controls [PSP: $t(43) = -3.79$, $P < 0.001$; Parkinson's disease: $t(48) = -2.76$, $P < 0.01$] and total ACE-R scores [PSP: $t(43) = -5.74$, $P < 0.00001$; Parkinson's disease: $t(48) = -2.63$, $P < 0.05$]. Patients with PSP also had lower ACE-R [$t(41) = -3.04$, $P < 0.01$] and marginally lower MMSE [$t(41) = -1.95$, $P = 0.06$] than patients with Parkinson's disease.

Behavioural results are shown in Fig. 2. There were significant group differences in the omission error in the Go condition [$F(2,68) = 12.37$, $P < 0.0001$; partial $\eta^2 = 0.27$], and in the commission error in the No-Go condition [$F(2,68) = 7.20$, $P < 0.001$; partial $\eta^2 = 0.18$]. Compared with controls, both patient groups had higher omission errors [PSP: $t(43) = 4.45$, $P < 0.0001$; Parkinson's disease: $t(48) = 3.58$, $P < 0.001$] and higher commission errors [PSP: $t(43) = 3.42$, $P < 0.001$; Parkinson's

disease: $t(48) = 3.27$, $P < 0.01$]. Patients with PSP had higher omission errors than patients with Parkinson's disease [$t(41) = 2.49$, $P < 0.05$], and the two patient groups had similar commission errors [$t(41) = 0.83$, $P = 0.41$]. There was no significant group difference in the saccadic latency in successful Go trials [$F(2,68) = 2.34$, $P = 0.10$; partial $\eta^2 = 0.07$] or No-Go trials with commission errors [$F(2,68) = 1.65$, $P = 0.20$; partial $\eta^2 = 0.05$].

Hierarchical drift-diffusion model fit to saccadic Go/No-Go data

We compared four variants of the hierarchical DDM for the saccadic Go/No-Go task, varying systematically in constraints on whether the starting point was biased towards one of the two decision boundaries, and whether the drift rate varied between Go and No-Go conditions, because the drift rate is often assumed to change between stimulus conditions (Gomez *et al.*, 2007). For each model, a Bayesian parameter estimation procedure was used to estimate the joint posterior distributions of all the model parameters, given the observed behavioural data. To identify the model with the best fit, we estimated the deviance information criterion (DIC) value of each model, a goodness-of-fit measure for Bayesian models with a penalty for additional free model parameters (Spiegelhalter *et al.*, 2002).

The best model (with the lowest DIC value) to describe the data across Go/No-Go conditions and participants had a variable starting point between participants and variable drift rates between Go and No-Go conditions (Model 4 in Fig. 3A, see also Fig. 3B). To evaluate the model fit, we compared posterior model predictions with the observed data. The posterior predictions of the best model were generated by averaging 500 simulations of the same amount of model predicted data as observed in the experiment using posterior parameter estimates. There was a good agreement between the observed data and the model predictions across conditions in all three participant groups (Fig. 3C).

Inferences from model parameters

Figure 4 shows the posterior parameter estimates for the three participant groups. We used both frequentist and Bayesian statistics to examine group differences in model parameters.

Response bias

The starting point was significantly larger than 0.5 in all three groups [PSP: $t(18) = 13.10$, $P < 1 \times 10^{-9}$, $P_{P|D} \approx 1$; Parkinson's disease: $t(23) = 7.85$, $P < 1 \times 10^{-7}$, $P_{P|D} \approx 1$; control: $t(25) = 9.52$, $P < 1 \times 10^{-9}$, $P_{P|D} \approx 1$], indicating that there is a prepotent bias towards the Go response (i.e. the upper decision boundary). However, the absolute magnitude was small in healthy controls and we observed a significant difference in the response bias between groups [$F(2,68) = 18.16$, $P < 0.000001$, partial $\eta^2 = 0.36$]. No

Figure 2 Behavioural results. The mean proportion of errors (*top*) and saccadic latencies (*bottom*) in the Go/No-Go task. The error bars represent the standard errors across participants in each group. In all panels, asterisks denote statistical significance at *P < 0.05, **P < 0.01, or ***P < 0.001 from independent sample *t*-tests and n.s. denotes non-significant difference. PD = Parkinson's disease.

significant difference was observed between patients with Parkinson's disease and controls [$t(48) = 1.28$, $P = 0.21$, $P_{P|D} = 0.86$]. The PSP group had a significantly larger bias towards the Go response than the Parkinson's group [$t(41) = 4.20$, $P < 0.001$, $P_{P|D} \approx 1$] and controls [$t(43) = 6.14$, $P < 0.000001$, $P_{P|D} \approx 1$], indicating that despite their difficulty in moving because of akinetic rigidity, patients with PSP are actually close to the movement threshold.

Accumulation of evidence for the response

There was a significant group difference in the drift rate in both Go and No-Go conditions [Go: $F(2,68) = 36.68$, $P < 1 \times 10^{-10}$, partial $\eta^2 = 0.53$; No-Go: $F(2,68) = 4.38$, $P < 0.05$, partial $\eta^2 = 0.12$]. The drift rate in the Go condition was lower in the PSP group than that in the Parkinson's disease group [$t(41) = 2.96$, $P < 0.01$, $P_{P|D} = 0.99$] and controls [$t(43) = 6.54$, $P < 1 \times 10^{-7}$, $P_{P|D} \approx 1$], whereas the patients with Parkinson's disease also had a lower Go drift rate than the controls [$t(48) = -6.54$, $P < 1 \times 10^{-7}$, $P_{P|D} \approx 1$]. For the No-Go condition, both patient groups had lower drift rate than controls [PSP: $t(43) = -2.33$, $P < 0.05$, $P_{P|D} = 0.98$; Parkinson's disease: $t(48) = -3.02$, $P < 0.01$, $P_{P|D} = 0.99$], but no significant difference was observed between the two patient groups [$t(41) = 0.25$, $P = 0.80$, $P_{P|D} = 0.61$].

Non-decision time and boundary separation

The three participant groups significantly differed in their non-decision time [$F(2,68) = 15.63$, $P < 0.00001$, partial $\eta^2 = 0.32$]. Both patient groups had a shorter non-decision

time than controls [PSP: $t(43) = -4.54$, $P < 0.0001$, $P_{P|D} \approx 1$; Parkinson's disease: $t(48) = -4.30$, $P < 0.0001$, $P_{P|D} \approx 1$], and the non-decision time was similar between the two patient groups [$t(41) = 0.89$, $P = 0.38$, $P_{P|D} = 0.74$]. The three participant groups had similar boundary separation between thresholds for Go and No-Go decisions [$F(2,68) = 0.14$, $P = 0.87$, partial $\eta^2 = 0.004$].

Model-based classification

We used a leave-one-out cross validation procedure in a three-way classification of participant groups (PSP, Parkinson's disease, and controls). First we used the four raw behavioural measures (commission error, omission error, saccadic latency distributions in the Go and No-Go conditions) as the feature space. As expected from the descriptive statistics and group contrasts, there was only a modest ability to classify participants, such that 50–60% of patients were correctly classified (Table 2). The associated ROC curves illustrate the limited performance of behavioural measures, and in particular, show limited discrimination of the two patient groups (Fig. 5).

We then used the model parameters as a second feature space for classification using the same cross-validation procedure. The model-based approach showed superior sensitivity and precision in classification across the three groups (>75%) (Table 2). The accompanying ROC curves illustrate the significant enhanced ability of model parameters to differentiate participants (Fig. 5). The significant improvement in classification using model parameters over

Figure 3 Model comparison and model fits. (**A**) The deviance information criterion (DIC) value differences between the best fit model (Model 4) and the other three model variants, for each group separately (dash lines) and all participants combined (solid lines). (**B**) The graphical representation of the best fit model. The shaded node Data(g,p,i,j) indicates the observed data of each group (g), participant (p), condition (i) and trial (j). Nodes a, T_{er}, z, and v are parameters of the drift-diffusion model, each with a group distribution for each patient group with mean μ and standard deviation σ. (**C**) Posterior predictive data distributions from the best fit model. The distribution along the positive x-axis shows the latency distribution in the Go condition (correct Go trials), and the distribution along the negative x-axis shows the latency distribution in the No-Go condition (commission error trials). Each panel shows the normalized histograms of the observed data and the model prediction (black lines). The area under the curve on the positive x-axis corresponds to the observed and predicted accuracy in the Go condition. The area under the curve along the negative x-axis corresponds to the commission error in the No-Go condition. PD = Parkinson's disease.

raw behavioural data was confirmed with permutation tests.

Discussion

We confirmed the impairment of response inhibition in patients with PSP and Parkinson's disease, but identified significant differences in these disorders on the decision processes that lead to disinhibition. Both patient groups made more commission errors despite akinesia (O'Sullivan et al., 2010; Nombela et al., 2014). However, the striking result in PSP was that patients were strongly biased towards making a response and yet were severely impaired at accumulating the necessary evidence to commit to that response (Fig. 4E). This combination provides a

parsimonious explanation for the apparently paradoxical combination of impulsivity and akinesia seen in this disease.

The study highlights the benefits of formal computational modelling of behaviour for a better understanding of disease mechanisms. Bayesian parameter estimation of the drift-diffusion model provided a highly efficient and robust measure of an individual's performance, with many fewer data needed in comparison with other approaches in preclinical and normative studies (Vandekerckhove et al., 2011; Wiecki et al., 2013; Zhang and Rowe, 2014). This approach enables one to infer disease-specific changes at the group level.

The model decomposed behavioural data into five parameters associated with Go/No-Go decisions: response bias, drift rates in Go and No-Go conditions, boundary

Figure 4 Posterior estimates of the hierarchical drift-diffusion model parameters for each group. (**A**) Response bias *z*. (**B**) Non-decision time T_{er} (**C**) Draft rates *v* for Go (solid lines) and No-Go (dashed lines) conditions. (**D**) Boundary separation *a*. In all panels, the asterisks denote significant difference between PSP and patients Parkinson's disease from frequentist and Bayesian statistics, and n.s. denotes non-significant difference. (**E**) The schematic diagram of the altered Go/No-go decision processes in patients. PSP leads to an exaggerated response bias towards Go decisions (i.e. the upper boundary), and a reduced non-decision time, but that the further accumulation of evidence towards a response is accumulated very slowly, predisposing patients to inhibition errors but without prolonged latencies of actual responses. In contrast, Parkinson's disease leads to a shorter non-decision time but normal initial response bias and a mild reduction in the rate of accumulation of evidence. PD = Parkinson's disease.

separation and non-decision time. These model parameters also improved the discrimination of patients and controls over the common behavioural measures (errors and reaction times), with higher precision and superior signal detection in classification (as receiver operating characteristics). Simple behavioural measures, like the mean latency of response, have been examined before in both diseases, but with mixed conclusions. In patients with Parkinson's disease, pro-saccades may have longer latency to controls (Michell *et al.*, 2006) or normal (Chan *et al.*, 2005; van Koningsbruggen *et al.*, 2009), and reflective saccades may be faster (Briand *et al.*, 2001). Horizontal saccadic latency in PSP has been reported to be either slower than controls (Linder *et al.*,

2012; Ghosh *et al.*, 2013) or normal, at least at the group level (Pierrot-Deseilligny *et al.*, 1989; Vidailhet *et al.*, 1994). By using the full distribution of response latencies and accuracy, the model-based approach instead provides clear evidence of abnormality in both PSP and Parkinson's disease. This result implies that data analysis methods for disease monitoring or drug response monitoring need to be more sophisticated than basic behavioural measures. The effect of a candidate drug on behaviour may be missed if crude metrics like reaction time alone are used. Our modelling approach has greater potential to support clinical trials.

The model-based analysis revealed that behavioural impairments of response inhibition in PSP and Parkinson's

Table 2 Leave-one-out cross-validation results from three-way linear logistic regression classifiers

Feature sets	True positive rate				Precision				AUC of ROC curves			
	PSP group	PD group	Control group	Weighted average	PSP group	PD group	Control group	Weighted average	PSP group	PD group	Control group	Weighted average
DDM parameters	0.73	0.67	0.85	0.75	0.82	0.73	0.73	0.76	0.92	0.81	0.93	0.89
Behavioural measures	0.63	0.50	0.77	0.64	0.75	0.55	0.65	0.64	0.82	0.66	0.85	0.78
Permutation P-values for DDM superiority			$P < 0.05$				$P = 0.07$				$P < 0.0001$	

Permutation tests were used to compare the classification results based on DDM parameters and raw behavioural measures. For classification based on DDM parameters, three PSP patients were misclassified as controls and two as Parkinson's disease (PD) patients; while five patients with Parkinson's disease were misclassified as controls and three as patients with PSP. For classification based on behavioural measures, two patients with PSP were misclassified as controls and five as patients with Parkinson's disease; whereas nine patients with Parkinson's disease were misclassified as controls and three as patients with PSP.

Figure 5 Receiver operating characteristic curves of each class in the leave-one-out three-way classification based on the model parameters (solid lines) and raw behavioural measures (dash lines). PD = Parkinson's disease.

disease arise for different reasons. This implies that effective treatment strategies for one disease may not work for the other. However, in both patient groups and controls, a response bias towards Go decisions was consistently observed. This could be explained by the reactive nature of Go saccades and an underlying bias in response neuron populations. For example, neurons in the intermediate layer of the superior colliculus have stronger sustained activities in Go trials than No-Go trials (Paré and Wurtz, 2001), which might enhance descending supranuclear control for saccades.

Patients with PSP demonstrated more severe response bias than patients with Parkinson's disease and control subjects, which could be explained by several pathophysiological mechanisms. Abnormal ocular fixation, such as square wave jerks, is more apparent in PSP (Garbutt et al., 2004; Otero-Millan et al., 2011) than in Parkinson's disease (Rascol et al., 1991). This has been attributed to midbrain atrophy in PSP (Kato et al., 2003). The disease interrupts inputs to omnipause neurons (e.g. from rostral superior colliculus, see Everling et al., 1998), which in turn changes the reciprocal discharge patterns of omnipause neurons and burst neurons in the pontine

reticular formation. At the behavioural level, the affected brainstem circuitry would be prone to initiate saccades, leading to a strong bias towards Go responses in the Go/No-Go task.

It is also worth considering the contribution of cortical pathology. ^{18}F-fluorodeoxyglucose PET imaging has identified decreased metabolic activity in the medial prefrontal cortex, anterior cingulate, and ventrolateral prefrontal cortex in PSP (Eckert et al., 2008). These regions are part of the cortical network essential for executive control (Ridderinkhof et al., 2004) and response inhibition of both eye and hand movements (Leung and Cai, 2007). Therefore severe response bias in PSP may also result from cortical degeneration, which imbalances the binary decision between Go and No-Go choices (Mulder et al., 2012).

Patients' with PSP and Parkinson's disease had slower drift rates than controls in both Go and No-Go conditions. This result suggests the effects of the diseases on the accumulation of decision signal: prolonging the latency to reach a decision boundary and thereby increasing response errors. Previous work on Parkinson's disease is consistent with this account. Briand et al. (1999) showed longer

saccadic latency in patients with Parkinson's disease in an anti-saccade task (Antoniades *et al.*, 2013). Similar results were reported in studies using pro-saccade paradigms (Amador *et al.*, 2006; Michell *et al.*, 2006) and manual reaction time tasks (Gauntlett-Gilbert and Brown, 1998). Using voxel-based morphometry, Perneczky *et al.* (2011) identified that the longer and more variable saccadic latency in patients with Parkinson's disease was associated with lower grey matter volume of the frontal eye field and lateral prefrontal cortex. The frontal-subcortical pathway plays a central role for the generation of saccades with precise timing (Robinson and Fuchs, 2001), and the accurate saccade control in response to different task demands via the prefrontotectal tract (Robinson and Fuchs, 2001). In Parkinson's disease, cortical and subcortical atrophy disrupts this saccadic decision network (Tinaz *et al.*, 2011; Rae *et al.*, 2012), which may give rise to the lowered drift rates observed in the current study. Similarly, prolonged pro-saccade latencies have also been reported in PSP (Ghosh *et al.*, 2010). We speculate that this is also caused by atrophy in saccadic control regions (Ghosh *et al.*, 2012), which is yet to be confirmed in imaging studies that correlate with saccade latency.

An intriguing finding is that patients with PSP and those with Parkinson's disease had shorter non-decision time than controls. The non-decision time reflects the latency of early sensory encoding external to the oculomotor decision process (Ratcliff and McKoon, 2008; Wagenmakers, 2009). Therefore, shorter non-decision time could imply enhanced early sensory processing in patients. This result may at first seem surprising, given motor akinesia and cognitive slowing associated with the diseases. Nevertheless, our result is consistent with EEG evidence. In a visual oddball paradigm, the latency of the early event-related potential N1 in patients with Parkinson's disease was shorter than that in healthy control subjects (Wang *et al.*, 2001; Li *et al.*, 2003), suggesting excessive attention or enhanced sensory processing in patients. This concurs with the hypothesis (Palop *et al.*, 2006) that impaired cognitive function in neurodegenerative disorders can be compensated for by additional processing, such as increased reliance on visual features (Bloem *et al.*, 2004; Helmich *et al.*, 2007).

In both PSP and Parkinson's disease there is abundant evidence for impulsive limb movements and global behaviours (Litvan *et al.*, 1996a; Aarsland *et al.*, 2001; Robert *et al.*, 2009; O'Sullivan *et al.*, 2010; Jahanshahi *et al.*, 2014; Nombela *et al.*, 2014). For example, patients with Parkinson's disease have higher commission errors than controls in manual Go/No-Go tasks (Nombela *et al.*, 2014), and longer stop-signal reaction time in manual stop-signal tasks (Gauggel *et al.*, 2004; Ye *et al.*, 2014a). Therefore the failure of response inhibition is not restricted to eye movements as studied here. It is possible that the origin of limb inhibition deficits is different to oculomotor inhibition deficits, but we propose that the two types of decision deficit are homologous. Several lines of research support this hypothesis. For instance, limb kinetics affect

saccadic outputs in health (Snyder *et al.*, 2002; van Donkelaar *et al.*, 2004), and both are comparably impaired in Parkinson's disease (Gibson *et al.*, 1987). Onset latencies for eye and hand movements are correlated in many tasks (Lunenburger *et al.*, 2000; Sailer *et al.*, 2000; Gribble *et al.*, 2002; Snyder *et al.*, 2002), including in stop-signal tasks (Boucher *et al.*, 2007). Furthermore, the same accumulator model, assuming competitions between a Go process and a Stop process during response inhibition, provides a good fit for data from both saccadic and manual stop-signal tasks (De Jong *et al.*, 1990; Hanes *et al.*, 1998; Gopal and Murthy, 2015). Therefore, although the inhibited movements of saccades and manual movements are not controlled by an identical anatomical pathway, different inhibitory systems may share the same computational principals: disruption to this process therefore gives rise to similar impulsivity across response modalities in diseases. This account is consistent with the findings that deep brain stimulation in Parkinson's disease influences inhibitory controls over saccadic as well as manual responses (van den Wildenberg *et al.*, 2006; Yugeta *et al.*, 2010; Swann *et al.*, 2011; Jahanshahi, 2013).

There are several limitations to this study. First, the severe response bias towards Go decisions indicates that PSP is associated with impulsivity in saccadic inhibition. However, impulsivity is a multi-modal construct (Dalley *et al.*, 2011) and our study alone does not show whether performance impairments in behavioural paradigms such as the Go/No-Go task are associated with different domains of cognition and impulsivity. Saccadic latencies target impaired decision processes in the cortical and subcortical supranuclear network and cognitive precursors to oculomotor inhibition. This is not necessarily a sensitive measure of a broad range of other higher-order cognitive deficits in Parkinson's disease and PSP (Burrell *et al.*, 2014; Yarnall *et al.*, 2014). Nevertheless, saccadic control involves widespread cortico-striato-thalamo-cortical circuits that are essential to cognition (Alexander *et al.*, 1990; Hikosaka *et al.*, 2000), which makes saccades a valuable tool for understanding cognitive dysfunctions (Leigh and Kennard, 2004). A recent study on the fractionation of impulsivity provides promising results in this regard. Commission errors in the saccadic Go/No-Go task, together with other tasks with demands on conflict resolution, are associated with the self-assessment of impulsive behaviours on the Barrett Impulsivity Scale (Nombela *et al.*, 2014), suggesting the sensitivity and broad relevance of saccadic tasks in relation to clinical features.

Second, we have reported that model parameters were more informative than the commonly derived behavioural measures (mean latencies and errors) in classification. This does not mean that the model parameters are more informative than the raw data, but reflects the fact that the model parameters are sensitive to higher order moments of the reaction time distributions, especially the skew, kurtosis and variance. Addition of these higher order moments might improve accuracy of classification, but would not

provide the mechanistic interpretation of the deficits as revealed from the DDM.

Finally, the patients were recruited from a regional clinic and therefore may not fully represent the whole population of patients at different disease stages. We included a modest number of patients in each group, which was sufficient for detecting disease-specific differences. Given the fact that saccadometry is well tolerated in patients, our protocol could be extended to a larger cohort, from which the increased statistical power would allow one to further investigate the association between model parameters and clinical measures. Interestingly, a recent longitudinal study showed that, in PSP, oculomotor function and cognition were affected early in the course of the illness (Ghosh *et al.*, 2013). Therefore, although our approach is potentially useful to explore the effects of treatment or disease on oculomotor and decision-making systems, model-based analysis of longitudinal data would be required to identify appropriate biomarkers for tracking disease progression in individual patients.

In conclusion, impairments of saccadic response inhibition occur in both PSP and Parkinson's disease. Both diseases impaired information sampling during decision-making, while patients with PSP showed an additional stronger, disease-specific bias towards Go decisions. We further demonstrated that computational modelling is more efficient than raw behavioural measures when used for discriminating between patients. These results have the potential to be exploited in future diagnostic and therapeutic studies for the comprehensive understanding of different disease mechanisms and in the evaluation of disease-modifying treatments.

Funding

References

Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 42–9.

Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog Brain Res 1990; 85: 119–46.

Amador SC, Hood AJ, Schiess MC, Izor R, Sereno AB. Dissociating cognitive deficits involved in voluntary eye movement dysfunctions in Parkinson's disease patients. Neuropsychologia 2006; 44: 1475–82.

Antoniades C, Ettinger U, Gaymard B, Gilchrist I, Kristjánsson A, Kennard C, et al. An internationally standardised antisaccade protocol. Vision Res 2013; 84: 1–5.

Averbeck BB, O'Sullivan SS, Djamshidian A. Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin. Psychol 2014; 10: 553–80.

Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77–100.

Berger JO, Bayarri MJ. The interplay of bayesian and frequentist analysis. Stat Sci 2004; 19: 58–80.

Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of Gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004; 19: 871–84.

Boucher L, Stuphorn V, Logan GD, Schall JD, Palmeri TJ. Stopping eye and hand movements: are the processes independent? Percept Psychophys 2007; 69: 785–801.

Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211.

Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75: 246–9.

Briand KA, Hening W, Poizner H, Sereno AB. Automatic orienting of visuospatial attention in Parkinson's disease. Neuropsychologia 2001; 39: 1240–9.

Briand KA, Strallow D, Hening W, Poizner H, Sereno AB. Control of voluntary and reflexive saccades in Parkinson's disease. Exp Brain Res 1999; 129: 38–48.

Brunton BW, Botvinick MM, Brody CD. Rats and humans can optimally accumulate evidence for decision-making. Science 2013; 340: 95–8.

Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord 2014; 29: 684–93.

Cavanagh JF, Wiecki TV, Cohen MX, Figueroa CM, Samanta J, Sherman SJ, et al. Subthalamic nucleus stimulation reverses mediofrontal influence over decision threshold. Nat Neurosci 2011; 14: 1462–7.

Chan F, Armstrong IT, Pari G, Riopelle RJ, Munoz DP. Deficits in saccadic eye-movement control in Parkinson's disease. Neuropsychologia 2005; 43: 784–96.

Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron 2011; 69: 680–94.

Van Donkelaar P, Siu KC, Walterschied J. Saccadic output is influenced by limb kinetics during eye-hand coordination. J Mot Behav 2004; 36: 245–52.

Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008; 23: 727–33.

Everling S, Paré M, Dorris MC, Munoz DP. Comparison of the discharge characteristics of brain stem omnipause neurons and superior colliculus fixation neurons in monkey: implications for control of fixation and saccade behavior. J Neurophysiol 1998; 79: 511–28.

Fahn S. Recent developments in Parkinson's disease. New York: Raven Press; 1986.

Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007; 318: 1309–12.

Gamerman D, Lopes HF. Markov chain monte carlo: stochastic simulation for bayesian inference. 2nd edn. London: Taylor and Francis; 2006.

Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75: 1386–94.

Gauggel S, Rieger M, Feghoff TA. Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 539–44.

Gauntlett-Gilbert J, Brown VJ. Reaction time deficits and Parkinson's disease. Neurosci Biobehav Rev 1998; 22: 865–81.

Gelman A, Carlin J, Stern H, Rubin D. Bayesian data analysis. 2nd edn. Boca Raton, FL: Chapman & Hall/CRC Press; 2004.

Ghosh B, Rowe JB, Carpenter RHS, Calder AJ, Peers PV, Lawrence AD, et al. PAW20 Saccadic correlates of cognition in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2010; 81: e29.

Ghosh BCP, Calder AJ, Peers PV, Lawrence AD, Acosta-Cabronero J, Pereira JM, et al. Social cognitive deficits and their neural correlates in progressive supranuclear palsy. Brain 2012; 135: 2089–102.

Ghosh BCP, Carpenter RHS, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy. PLoS One 2013; 8: e74486.

Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–52.

Gibson JM, Pimlott R, Kennard C. Ocular motor and manual tracking in Parkinson's disease and the effect of treatment. J Neurol Neurosurg. Psychiatry 1987; 50: 853–60.

Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130: 1552–65.

Gomez P, Ratcliff R, Perea M. A model of the go/no-go task. J Exp Psychol Gen 2007; 136: 389–413.

Gopal A, Murthy A. Eye-hand coordination during a double-step task: evidence for a common stochastic accumulator. J Neurophysiol 2015; 114: 1438–54.

Gribble PL, Everling S, Ford K, Mattar A. Hand-eye coordination for rapid pointing movements: arm movement direction and distance are specified prior to saccade onset. Exp Brain Res 2002; 145: 372–82.

Hanes DP, Patterson WF, Schall JD. Role of frontal eye fields in countermanding saccades: visual, movement, and fixation activity. J Neurophysiol 1998; 79: 817–34.

Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015–19.

Helmich RC, de Lange FP, Bloem BR, Toni I. Cerebral compensation during motor imagery in Parkinson's disease. Neuropsychologia 2007; 45: 2201–15.

Hikosaka O, Takikawa Y, Kawagoe R. Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 2000; 80: 953–78.

Jahanshahi M, Obeso I, Baunez C, Alegre M, Krack P. Parkinson's disease, the subthalamic nucleus, inhibition, and impulsivity. Mov Disord 2014; 00: 1–13.

Jahanshahi M. Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease. Front Syst Neurosci 2013; 7: 118.

Jahfari S, Ridderinkhof KR, Scholte HS. Spatial frequency information modulates response inhibition and decision-making processes. PLoS One 2013; 8: e76467.

De Jong R, Coles MG, Logan GD, Gratton G. In search of the point of no return: the control of response processes. J Exp Psychol Hum Percept Perform 1990; 16: 164–82.

Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003; 210: 57–60.

Kim JN, Shadlen MN. Neural correlates of a decision in the dorsolateral prefrontal cortex of the macaque. Nat Neurosci 1999; 2: 176–85.

Van Koningsbruggen MG, Pender T, Machado L, Rafal RD. Impaired control of the oculomotor reflexes in Parkinson's disease. Neuropsychologia 2009; 47: 2909–15.

Kruschke J. Doing Bayesian data analysis: a tutorial introduction with R and BUGS. San Diego, CA: Academic Press/Elsevier; 2010.

Leigh RJ, Kennard C. Using saccades as a research tool in the clinical neurosciences. Brain 2004; 127: 460–77.

Leung HC, Cai W. Common and differential ventrolateral prefrontal activity during inhibition of hand and eye movements. J Neurosci 2007; 27: 9893–9900.

Li M, Kuroiwa Y, Wang L, Kamitani T, Takahashi T, Suzuki Y, et al. Early sensory information processes are enhanced on visual oddball and S1-S2 tasks in Parkinson's disease: a visual event-related potentials study. Park Relat Disord 2003; 9: 329–40.

Linder J, Wenngren BI, Stenlund H, Forsgren L. Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism. J Neurol 2012; 259: 1206–14.

Lindley DV. Introduction to probability and statistics from a bayesian viewpoint. Cambridge: Cambridge University Press; 1965.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 1996a; 47: 1–9.

Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996b; 55: 97–105.

Lunenburger L, Kutz DF, Hoffmann KP. Influence of arm movements on saccades in humans. Eur J Neurosci 2000; 12: 4107–16.

Michell AW, Xu Z, Fritz D, Lewis SJG, Foltynie T, Williams-Gray CH, et al. Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res 2006; 174: 7–18.

Mulder MJ, Wagenmakers EJ, Ratcliff R, Boekel W, Forstmann BU. Bias in the Brain: a diffusion model analysis of prior probability and potential payoff. J Neurosci 2012; 32: 2335–43.

Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple modes of impulsivity in Parkinson's disease. PLoS One 2014; 9: e85747.

O'Sullivan SS, Djamshidian A, Ahmed Z, Evans AH, Lawrence AD, Holton JL, et al. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov Disord 2010; 25: 638–42.

Ober JK, Przedpelska-Ober E, Gryncewicz W, Dylak J, Carpenter RH, Ober JJ. Hand-held system for ambulatory measurement of saccadic durations of neurological patients. In: Gajda J., editor. Modelling and Measurement in Medicine Komitet Biocybernityki i Inzyneierii Biomedycznej. Warsaw: PAN; 2003. p. 187–98.

Obeso I, Wilkinson L, Casabona E, Bringas ML, Álvarez M, Álvarez L, et al. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res 2011; 212: 371–84.

Obeso I, Wilkinson L, Casabona E, Speekenbrink M, Bringas ML, Álvarez M, et al. The subthalamic nucleus and inhibitory control: impact of subthalamotomy in Parkinson's disease. Brain 2014; 137: 1470–80.

Otero-Millan J, Serra A, Leigh RJ, Troncoso XG, Macknik SL, Martinez-Conde S. Distinctive features of saccadic intrusions and microsaccades in progressive supranuclear palsy. J Neurosci 2011; 31: 4379–87.

Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006; 443: 768–73.

Paré M, Wurtz RH. Progression in neuronal processing for saccadic eye movements from parietal cortex area lip to superior colliculus. J Neurophysiol 2001; 85: 2545–62.

Perneczky R, Ghosh BCP, Hughes L, Carpenter RHS, Barker RA, Rowe JB. Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. Neurobiol Dis 2011; 43: 79–85.

Pierrot-Deseilligny C, Rivaud S, Pillon B, Fournier E, Agid Y. Lateral visually-guided saccades in progressive supranuclear palsy. Brain 1989; 112: 471–87.

Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 2012; 62: 1675–84.

Rascol O, Sabatini U, Simonetta-Moreau M, Montastruc JL, Rascol A, Clanet M. Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991; 54: 599–602.

Ratcliff R, Cherian A, Segraves M. A comparison of macaque behavior and superior colliculus neuronal activity to predictions from models of two-choice decisions. J Neurophysiol 2003; 90: 1392–407.

Ratcliff R, Gomez P, McKoon G. A diffusion model account of the lexical decision task. Psychol Rev 2004; 111: 159–82.

Ratcliff R, McKoon G. The diffusion decision model: theory and data for two-choice decision tasks. Neural Comput 2008; 20: 873–922.

Ratcliff R, Smith PL. A comparison of sequential sampling models for two-choice reaction time. Psychol Rev 2004; 111: 333–67.

Ridderinkhof KR, Van Den Wildenberg WPM, Segalowitz SJ, Carter CS. Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. Brain Cogn 2004; 56: 129–40.

Robert G, Drapier D, Verin M, Millet B, Azulay JP, Blin O. Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology. Mov Disord 2009; 24: 2316–27.

Robinson FR, Fuchs AF. The role of the cerebellum in voluntary eye movements. Annu Rev Neurosci 2001; 24: 981–1004.

Rowe JB, Hughes L, Nimmo-Smith I. Action selection: a race model for selected and non-selected actions distinguishes the contribution of premotor and prefrontal areas. Neuroimage 2010; 51: 888–96.

Sailer U, Eggert T, Ditterich J, Straube A. Spatial and temporal aspects of eye-hand coordination across different tasks. Exp Brain Res 2000; 134: 163–73.

Shadlen MN, Newsome WT. Neural basis of a perceptual decision in the parietal cortex (Area LIP) of the rhesus monkey. J Neurophysiol 2001; 86: 1916–36.

Snyder LH, Calton JL, Dickinson AR, Lawrence BM. Eye-hand coordination: saccades are faster when accompanied by a coordinated arm movement. J Neurophysiol 2002; 87: 2279–86.

Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol 2002; 64: 583–639.

Swann N, Poizner H, Houser M, Gould S, Greenhouse I, Cai W, et al. Deep brain stimulation of the subthalamic nucleus alters the cortical profile of response inhibition in the beta frequency band: a scalp EEG study in Parkinson's disease. J Neurosci 2011; 31: 5721–29.

Tinaz S, Courtney MG, Stern CE. Focal cortical and subcortical atrophy in early Parkinson's disease. Mov Disord 2011; 26: 436–41.

Vandekerckhove J, Tuerlinckx F, Lee MD. Hierarchical diffusion models for two-choice response times. Psychol Methods 2011; 16: 44–62.

Verbruggen F, Logan GD. Models of response inhibition in the stop-signal and stop-change paradigms. Neurosci Biobehav Rev 2009; 33: 647–61.

Vidailhet M, Rivaud S, Gouider-Khouja N, Pillon B, Bonnet AM, Gaymard B, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994; 35: 420–26.

Wagenmakers EJ. Methodological and empirical developments for the Ratcliff diffusion model of response times and accuracy. Eur J Cogn Psychol 2009; 21: 641–71.

Wang L, Kuroiwa Y, Li M, Wang J, Kamitani T. Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease? Doc Ophthalmol 2001; 102: 83–93.

Wedderburn C, Wear H, Brown J, Mason SJ, Barker RA, Hodges J, et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008; 79: 500–3.

Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.

Wiecki TV, Sofer I, Frank MJ. HDDM: Hierarchical Bayesian estimation of the Drift-Diffusion Model in Python. Front Neuroinform 2013; 7: 14.

Van den Wildenberg WPM, van Boxtel GJM, van der Molen MW, Bosch DA, Speelman JD, Brunia CHM. Stimulation of the subthalamic region facilitates the selection and inhibition of motor responses in Parkinson's disease. J Cogn Neurosci 2006; 18: 626–36.

Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD Study. Neurology 2014; 82: 308–16.

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain 2014a; 137: 1145–55.

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Improving response inhibition in parkinson's disease with atomoxetine. Biol Psychiatry 2014b; 77: 740–8

Yugeta A, Terao Y, Fukuda H, Hikosaka O, Yokochi F, Okiyama R, et al. Effects of STN stimulation on the initiation and inhibition of saccade in parkinson disease. Neurology 2010; 74: 743–8.

Zhang J, Hughes LE, Rowe JB. Selection and inhibition mechanisms for human voluntary action decisions. Neuroimage 2012; 63: 392–402.

Zhang J, Rowe JB. Dissociable mechanisms of speed-accuracy tradeoff during visual perceptual learning are revealed by a hierarchical drift-diffusion model. Front. Neurosci 2014; 8: 1–13.